Aeovian Pharmaceuticals Inc. has divulged new ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors potentially useful for the treatment of neurodegeneration, inflammation, fibrosis, systemic scleroderma, vascular disorders, Duchenne muscular dystrophy, liver and metabolic diseases, among others.